India's drug regulator has ordered immediate safety label updates for five widely used antimicrobial medicines after fresh data identified previously unlisted adverse drug reactions. According to reports from Mint, the Central Drugs Standard Control Organization (CDSCO) directed state licensing authorities on 6 July to ensure that manufacturers revise the prescribing information leaflets and promotional literature for tetracycline, vancomycin, metronidazole, cotrimoxazole, and oral itraconazole. The directive, issued by the Office of the Drugs Controller General (India) on July 6, 2026, follows a multi-stage pharmacovigilance assessment undertaken under the Pharmacovigilance Programme of India (PvPI) and subsequent expert review by the Subject Expert Committee (SEC) on Antimicrobial & Antiparasitic Drugs.
The move follows a review of adverse-event reports submitted under the Pharmacovigilance Programme of India (PvPI) and safety assessments endorsed by relevant subject expert committees. As reported by Mint, the updated warnings are intended to alert doctors and patients to rare but potentially serious reactions that surfaced after the medicines entered widespread clinical use, ranging from localized rashes to severe hypersensitivity reactions. The National Coordination Centre for Pharmacovigilance Programme of India (NCCPvPI) forwarded recommendations arising from the assessment of Adverse Drug Reaction (ADR) reports pertaining to Vancomycin formulations, which was discussed in 25th Signal Review Panel dated 30th October, 2024. The Patient Population Incidence - Adverse Drug Reactions (PPIs-ADR) based on Individual Case Study Reports (ICSR) were evaluated to make recommendations to CDSCO.
Under the revised safety guidance, manufacturers of tetracycline, metronidazole and cotrimoxazole must add fixed drug eruption (FDE) to the list of adverse drug reactions in the prescribing information. According to Mint, vancomycin must now carry a warning on DRESS syndrome—a rare but potentially life-threatening hypersensitivity reaction marked by widespread rash, fever and internal organ damage. The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome is characterized by fever, extensive skin rash, facial swelling, enlarged lymph nodes, eosinophilia, and involvement of internal organs such as the liver, kidneys, lungs, and heart. Manufacturers of oral itraconazole have been directed to include symmetrical drug-related intertriginous and flexural exanthema, a distinctive rash affecting skin folds such as the groin and armpits.
The regulatory action affects medicines used for various bacterial and parasitic infections, including tetracycline for bacterial infections like acne and respiratory tract issues, vancomycin for severe bacterial infections, metronidazole for bacterial and parasitic infections, cotrimoxazole for urinary and chest infections, and oral itraconazole for fungal infections. As reported by Crisil Market Intelligence and Analytics, the market size of the anti-infective segment in India stood at about ₹251.3 billion for FY2024. The updated labeling requirements will require manufacturers to incorporate the new safety information into their Package insert/Promotional Literature for all vancomycin formulations under their jurisdiction.
